Compare State Street SPDR S&P Biotech ETF (XBI) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs Zscaler Inc — how do they compare? State Street SPDR S&P Biotech ETF trades at $159.85, while Zscaler Inc trades at $166 (market cap $27.08B). The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals.
| XBI | ZS | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $169.55 | $336.27 |
52-Week Low | $93.43 | $118.05 |
Market Cap | — | $27.08B |
Enterprise Value | — | $25.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Zscaler (ZS) trades at $161.94, down 4.63% today, reflecting bearish technical signals despite strong quarterly earnings beats. Revenue growth remains robust at 25% year-over-year in Q4 2026, though net income margins are negative. The stock faces headwinds from slowing growth guidance for FY2027 and elevated valuation multiples, with a consensus price target of $204.88 suggesting 26% upside. Recent news highlights AI security product launches and conference presentations.
Outlook is mixed: analyst sentiment is overwhelmingly bullish (79% buy ratings), but execution risks and decelerating top-line growth cloud near-term performance. Investment opportunity hinges on AI-driven cybersecurity demand offsetting margin pressures, while risks include competitive threats and capital expenditure increases impacting cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
